| review article | Q7318358 |
| scholarly article | Q13442814 |
| P2093 | author name string | David D'Cruz | |
| Natasha Jordan | |||
| P2860 | cites work | BAFF, a novel ligand of the tumor necrosis factor family, stimulates B cell growth | Q22009942 |
| TACI and BCMA are receptors for a TNF homologue implicated in B-cell autoimmune disease | Q22254041 | ||
| Cyclophosphamide versus methylprednisolone for treating neuropsychiatric involvement in systemic lupus erythematosus | Q24200954 | ||
| Cyclophosphamide versus methylprednisolone for treating neuropsychiatric involvement in systemic lupus erythematosus | Q24246092 | ||
| BLyS: member of the tumor necrosis factor family and B lymphocyte stimulator | Q28139180 | ||
| A cross-sectional study of clinical thrombotic risk factors and preventive treatments in antiphospholipid syndrome | Q28193536 | ||
| Interferon-inducible gene expression signature in peripheral blood cells of patients with severe lupus | Q28212039 | ||
| BAFF-R, a newly identified TNF receptor that specifically interacts with BAFF | Q28213294 | ||
| A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus | Q28254310 | ||
| Leflunomide: friend or foe for systemic lupus erythematosus? | Q28274721 | ||
| A new member of the immunoglobulin superfamily--CTLA-4 | Q28299244 | ||
| Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial | Q28304807 | ||
| Factors associated with damage accrual in patients with systemic lupus erythematosus: results from the Systemic Lupus International Collaborating Clinics (SLICC) Inception Cohort | Q28608340 | ||
| Efficacy and safety of epratuzumab in patients with moderate/severe active systemic lupus erythematosus: results from EMBLEM, a phase IIb, randomised, double-blind, placebo-controlled, multicentre study | Q28660706 | ||
| Efficacy and safety of abatacept in lupus nephritis: a twelve-month, randomized, double-blind study | Q44525390 | ||
| Intravenous cyclophosphamide and high dose corticosteroids improve MRI lesions in demyelinating syndrome in systemic lupus erythematosus. | Q44546201 | ||
| Risk factors for coronary heart disease in women with systemic lupus erythematosus: the Toronto Risk Factor Study | Q44652580 | ||
| Sequential therapies for proliferative lupus nephritis | Q44785533 | ||
| Long-term study of mycophenolate mofetil as continuous induction and maintenance treatment for diffuse proliferative lupus nephritis | Q44826001 | ||
| Clinical and immunologic effects of monthly administration of intravenous cyclophosphamide in severe systemic lupus erythematosus | Q44839857 | ||
| Prevention of renal damage in murine lupus nephritis by CTLA-4Ig and cyclophosphamide | Q44996901 | ||
| Disease control and safety of belimumab plus standard therapy over 7 years in patients with systemic lupus erythematosus | Q45237648 | ||
| Bone mineral density in postmenopausal Chinese patients with systemic lupus erythematosus | Q45307599 | ||
| Safety and pharmacodynamics of rontalizumab in patients with systemic lupus erythematosus: results of a phase I, placebo-controlled, double-blind, dose-escalation study. | Q45943683 | ||
| A retrospective seven-year analysis of the use of B cell depletion therapy in systemic lupus erythematosus at University College London Hospital: the first fifty patients | Q46067913 | ||
| A case of progressive multifocal leukoencephalopathy in a lupus patient treated with belimumab. | Q46097425 | ||
| Reduced B lymphocyte and immunoglobulin levels after atacicept treatment in patients with systemic lupus erythematosus: results of a multicenter, phase Ib, double-blind, placebo-controlled, dose-escalating trial | Q46353641 | ||
| Systemic lupus erythematosus in a multiethnic US cohort (LUMINA). XXV. Smoking, older age, disease activity, lupus anticoagulant, and glucocorticoid dose as risk factors for the occurrence of venous thrombosis in lupus patients | Q46443879 | ||
| Cutting edge: reversal of murine lupus nephritis with CTLA4Ig and cyclophosphamide | Q46448087 | ||
| Elevated levels of endogenous IL-6 in systemic lupus erythematosus. A putative role in pathogenesis. | Q46503835 | ||
| Treatment of murine lupus with CTLA4Ig | Q46538983 | ||
| Prevalence of and risk factors for low bone mineral density and vertebral fractures in patients with systemic lupus erythematosus. | Q46573574 | ||
| Effect of belimumab treatment on renal outcomes: results from the phase 3 belimumab clinical trials in patients with SLE. | Q46769274 | ||
| Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis | Q46818795 | ||
| IL-6 receptor blockage inhibits the onset of autoimmune kidney disease in NZB/W F1 mice | Q47901598 | ||
| Methotrexate treatment for refractory subacute cutaneous lupus erythematosus | Q77801983 | ||
| Prevalence and risk factors of carotid plaque in women with systemic lupus erythematosus | Q77909409 | ||
| Double blind, randomized, placebo controlled clinical trial of methotrexate in systemic lupus erythematosus | Q77919310 | ||
| Anti-interleukin-6 monoclonal antibody inhibits autoimmune responses in a murine model of systemic lupus erythematosus | Q79305119 | ||
| Mycophenolate mofetil and intravenous dexamethasone in the treatment of persistent lupus myelitis | Q79892757 | ||
| Differential effects of epratuzumab on peripheral blood B cells of patients with systemic lupus erythematosus versus normal controls | Q80730949 | ||
| Inflammatory myopathies | Q83164943 | ||
| Safety profile and clinical activity of sifalimumab, a fully human anti-interferon α monoclonal antibody, in systemic lupus erythematosus: a phase I, multicentre, double-blind randomised study | Q84614866 | ||
| Multitarget therapy for induction treatment of lupus nephritis: a randomized trial | Q85935694 | ||
| Tacrolimus is an effective treatment for lupus nephritis in pregnancy | Q88079375 | ||
| Efficacy and tolerability of methotrexate in antimalarial resistant lupus arthritis. | Q50904614 | ||
| "Nephritic flares" are predictors of bad long-term renal outcome in lupus nephritis. | Q50988300 | ||
| Effect of antimalarial agents on the fasting lipid profile in systemic lupus erythematosus. | Q51553735 | ||
| Prevalence and risk factors of osteoporosis in female SLE patients-extended report. | Q51753356 | ||
| Mycophenolate mofetil treatment in resistant myositis. | Q51784383 | ||
| Teratogenicity of mycophenolate confirmed in a prospective study of the European Network of Teratology Information Services. | Q52889724 | ||
| Tacrolimus versus mycophenolate mofetil for induction therapy of lupus nephritis: a randomised controlled trial and long-term follow-up. | Q53649024 | ||
| Efficacy and safety of methotrexate in recalcitrant cutaneous lupus erythematosus: results of a retrospective study in 43 patients. | Q53850772 | ||
| Mycophenolate versus Azathioprine as Maintenance Therapy for Lupus Nephritis | Q56335982 | ||
| Activation of type I interferon system in systemic lupus erythematosus correlates with disease activity but not with antiretroviral antibodies | Q56774177 | ||
| Role of the CTLA-4 receptor in T cell activation and immunity. Physiologic function of the CTLA-4 receptor | Q56907979 | ||
| Accelerated atherosclerosis in systemic lupus erythematosus: implications for patient management | Q57219130 | ||
| Cytokine IL-6 and IL-10 as Biomarkers in Systemic Lupus Erythematosus | Q58192318 | ||
| Successful treatment of generalized discoid skin lesions with azathioprine | Q70025640 | ||
| Pulse cyclophosphamide in the treatment of neuropsychiatric systemic lupus erythematosus | Q71538132 | ||
| Serum interferon levels in patients with systemic lupus erythematosus | Q72664589 | ||
| Bullous SLE: response to methotrexate and relationship with disease activity | Q73003179 | ||
| Age-specific incidence rates of myocardial infarction and angina in women with systemic lupus erythematosus: comparison with the Framingham Study | Q73106702 | ||
| Cyclophosphamide therapy for lupus nephritis: poor renal survival in black Americans. Glomerular Disease Collaborative Network | Q73182990 | ||
| Rapid improvement of subacute cutaneous lupus erythematosus with low-dose methotrexate | Q73426313 | ||
| Determination of prognosis in chronic disease, illustrated by systemic lupus erythematosus | Q73723971 | ||
| Experimental study on intramuscular injection of eukaryotic expression vector pcDNA3- IL-6 on BXSB mice | Q77736178 | ||
| Interferon and granulopoiesis signatures in systemic lupus erythematosus blood | Q29615064 | ||
| Efficacy and safety of atacicept for prevention of flares in patients with moderate-to-severe systemic lupus erythematosus (SLE): 52-week data (APRIL-SLE randomised trial). | Q30832522 | ||
| Long-term data on tacrolimus treatment in lupus nephritis | Q30835209 | ||
| Effect of hydroxychloroquine on the survival of patients with systemic lupus erythematosus: data from LUMINA, a multiethnic US cohort (LUMINA L) | Q31107094 | ||
| Factors associated with low bone mineral density in female patients with systemic lupus erythematosus | Q31984501 | ||
| A study of 20 SLE patients with intravenous immunoglobulin--clinical and serologic response | Q33330951 | ||
| Azathioprine therapy for patients with systemic lupus erythematosus | Q33336950 | ||
| Mycophenolate mofetil for non-renal manifestations of systemic lupus erythematosus: a systematic review | Q33377162 | ||
| Intravenous immunoglobulin therapy in systemic lupus erythematosus-associated thrombocytopenia | Q33392577 | ||
| The 10-year follow-up data of the Euro-Lupus Nephritis Trial comparing low-dose and high-dose intravenous cyclophosphamide | Q33401164 | ||
| Intermittent cyclophosphamide for the treatment of autoimmune thrombocytopenia in systemic lupus erythematosus | Q33405430 | ||
| Renal damage is the most important predictor of mortality within the damage index: data from LUMINA LXIV, a multiethnic US cohort | Q33411232 | ||
| Protective effect of hydroxychloroquine on renal damage in patients with lupus nephritis: LXV, data from a multiethnic US cohort | Q33455990 | ||
| Tocilizumab in systemic lupus erythematosus: data on safety, preliminary efficacy, and impact on circulating plasma cells from an open-label phase I dosage-escalation study | Q33527462 | ||
| Premature atherosclerosis in systemic lupus erythematosus | Q33893354 | ||
| Elevated serum B lymphocyte stimulator levels in patients with systemic immune-based rheumatic diseases. | Q33951524 | ||
| Premature coronary-artery atherosclerosis in systemic lupus erythematosus | Q33974685 | ||
| Efficacy of rituximab in 164 patients with biopsy-proven lupus nephritis: pooled data from European cohorts | Q34060110 | ||
| Traditional Framingham risk factors fail to fully account for accelerated atherosclerosis in systemic lupus erythematosus | Q34098573 | ||
| EULAR recommendations for the management of systemic lupus erythematosus with neuropsychiatric manifestations: report of a task force of the EULAR standing committee for clinical affairs | Q34132211 | ||
| European League Against Rheumatism recommendations for monitoring patients with systemic lupus erythematosus in clinical practice and in observational studies | Q34187282 | ||
| Azathioprine versus mycophenolate mofetil for long-term immunosuppression in lupus nephritis: results from the MAINTAIN Nephritis Trial | Q34409787 | ||
| Mycophenolate mofetil (CellCept): an alternative therapy for autoimmune inflammatory myopathy | Q34552973 | ||
| Reversal of aplastic anaemia secondary to systemic lupus erythematosus by high-dose intravenous cyclophosphamide | Q34763308 | ||
| Association of plasma B lymphocyte stimulator levels and disease activity in systemic lupus erythematosus | Q34802966 | ||
| B lymphocyte stimulator (BLyS) isoforms in systemic lupus erythematosus: disease activity correlates better with blood leukocyte BLyS mRNA levels than with plasma BLyS protein levels | Q34895937 | ||
| Initial clinical trial of epratuzumab (humanized anti-CD22 antibody) for immunotherapy of systemic lupus erythematosus | Q34897437 | ||
| Mycophenolate mofetil versus cyclophosphamide for induction treatment of lupus nephritis | Q34975939 | ||
| Prevention of cardiovascular disease in systemic lupus erythematosus--proposed guidelines for risk factor management | Q35179614 | ||
| Comparison of alternative primary outcome measures for use in lupus nephritis clinical trials | Q35430178 | ||
| Molecular basis for antagonistic activity of anifrolumab, an anti-interferon-α receptor 1 antibody | Q35545957 | ||
| Controlled clinical trial of IV cyclophosphamide versus IV methylprednisolone in severe neurological manifestations in systemic lupus erythematosus | Q35555433 | ||
| Rates of, and risk factors for, severe infections in patients with systemic autoimmune diseases receiving biological agents off-label | Q35617617 | ||
| Treatment of cutaneous lupus | Q35633324 | ||
| Interleukin-6 exacerbates glomerulonephritis in (NZB x NZW)F1 mice | Q35833886 | ||
| Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: the randomized, double-blind, phase II/III systemic lupus erythematosus evaluation of rituximab trial | Q35993027 | ||
| Atacicept in combination with MMF and corticosteroids in lupus nephritis: results of a prematurely terminated trial. | Q36085018 | ||
| Belimumab in the treatment of systemic lupus erythematosus: high disease activity predictors of response | Q36094045 | ||
| American College of Rheumatology guidelines for screening, treatment, and management of lupus nephritis | Q36221407 | ||
| Effects of belimumab, a B lymphocyte stimulator-specific inhibitor, on disease activity across multiple organ domains in patients with systemic lupus erythematosus: combined results from two phase III trials | Q36302240 | ||
| Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of adult and paediatric lupus nephritis | Q36302245 | ||
| Effect of prednisone and hydroxychloroquine on coronary artery disease risk factors in systemic lupus erythematosus: a longitudinal data analysis | Q36747001 | ||
| Sifalimumab, a human anti-interferon-α monoclonal antibody, in systemic lupus erythematosus: a phase I randomized, controlled, dose-escalation study | Q36844513 | ||
| Progressive multifocal leucoencephalopathy in the rheumatic diseases: assessing the risks of biological immunosuppressive therapies | Q37331090 | ||
| Influence of race/ethnicity on response to lupus nephritis treatment: the ALMS study | Q37462538 | ||
| Innovative uses of thalidomide | Q37761510 | ||
| Use of methotrexate in patients with systemic lupus erythematosus and primary Sjögren's syndrome | Q37806368 | ||
| Efficacy of mycophenolate mofetil in antimalarial-resistant cutaneous lupus erythematosus | Q37884880 | ||
| Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: the Lupus Nephritis Assessment with Rituximab study | Q38466691 | ||
| Mortality in systemic lupus erythematosus | Q38467155 | ||
| Role of intravenous cyclophosphamide in the treatment of severe neuropsychiatric systemic lupus erythematosus | Q40572101 | ||
| Azathioprine. An effective, corticosteroid-sparing therapy for patients with recalcitrant cutaneous lupus erythematosus or with recalcitrant cutaneous leukocytoclastic vasculitis | Q40750036 | ||
| Costimulatory B7 molecules in the pathogenesis of infectious and autoimmune diseases | Q41151737 | ||
| B-lymphocyte stimulator/a proliferation-inducing ligand heterotrimers are elevated in the sera of patients with autoimmune disease and are neutralized by atacicept and B-cell maturation antigen-immunoglobulin | Q41182083 | ||
| Efficacy and safety of subcutaneous tabalumab in patients with systemic lupus erythematosus: results from ILLUMINATE-1, a 52-week, phase III, multicentre, randomised, double-blind, placebo-controlled study | Q41418810 | ||
| Efficacy and safety of subcutaneous tabalumab, a monoclonal antibody to B-cell activating factor, in patients with systemic lupus erythematosus: results from ILLUMINATE-2, a 52-week, phase III, multicentre, randomised, double-blind, placebo-controll | Q41465773 | ||
| Premature morbidity from cardiovascular and cerebrovascular diseases in women with systemic lupus erythematosus | Q41608189 | ||
| Immune Interferon in the Circulation of Patients with Autoimmune Disease | Q41643954 | ||
| Systemic lupus erythematosus in three ethnic groups: XVI. Association of hydroxychloroquine use with reduced risk of damage accrual | Q41912319 | ||
| Recommendations on screening for chloroquine and hydroxychloroquine retinopathy: a report by the American Academy of Ophthalmology | Q41917354 | ||
| Longterm beneficial effect of chloroquine diphosphate on lipoprotein profile in lupus patients with and without steroid therapy | Q41919785 | ||
| The cholesterol lowering effect of antimalarial drugs is enhanced in patients with lupus taking corticosteroid drugs. | Q41924668 | ||
| Efficacy and safety of methotrexate in articular and cutaneous manifestations of systemic lupus erythematosus | Q41930370 | ||
| A randomized study of the effect of withdrawing hydroxychloroquine sulfate in systemic lupus erythematosus | Q41942545 | ||
| Low blood concentration of hydroxychloroquine is a marker for and predictor of disease exacerbations in patients with systemic lupus erythematosus | Q41944460 | ||
| Mycophenolate sodium for subacute cutaneous lupus erythematosus resistant to standard therapy | Q42616372 | ||
| Safety and efficacy of rituximab in systemic lupus erythematosus: results from 136 patients from the French AutoImmunity and Rituximab registry | Q42661986 | ||
| Efficacy and safety of epratuzumab in patients with moderate/severe flaring systemic lupus erythematosus: results from two randomized, double-blind, placebo-controlled, multicentre studies (ALLEVIATE) and follow-up | Q42694406 | ||
| The efficacy and safety of abatacept in patients with non-life-threatening manifestations of systemic lupus erythematosus: results of a twelve-month, multicenter, exploratory, phase IIb, randomized, double-blind, placebo-controlled trial | Q43038371 | ||
| Long-term efficacy and safety of rituximab in refractory and relapsing systemic lupus erythematosus | Q43064210 | ||
| Effect of antimalarials on thrombosis and survival in patients with systemic lupus erythematosus. | Q43417859 | ||
| Prospective observational single-centre cohort study to evaluate the effectiveness of treating lupus nephritis with rituximab and mycophenolate mofetil but no oral steroids. | Q43472878 | ||
| Impact of anti-interleukin-6 receptor blockade on circulating T and B cell subsets in patients with systemic lupus erythematosus | Q43551355 | ||
| Significantly higher estimated 10-year probability of fracture in lupus patients with bone mineral density comparable to that of healthy individuals | Q43624712 | ||
| Benefits of leflunomide in systemic lupus erythematosus: a pilot observational study | Q43692733 | ||
| Rituximab is an effective treatment for lupus nephritis and allows a reduction in maintenance steroids. | Q43699030 | ||
| Outcome and prognostic indicators of diffuse proliferative lupus glomerulonephritis treated with sequential oral cyclophosphamide and azathioprine | Q43959861 | ||
| Immunosuppressive therapy in lupus nephritis: the Euro-Lupus Nephritis Trial, a randomized trial of low-dose versus high-dose intravenous cyclophosphamide | Q43993205 | ||
| Successful treatment of subacute cutaneous lupus erythematosus with mycophenolate mofetil | Q44051927 | ||
| Successful IV pulse cyclophosphamide in refractory PM in 3 patients with SLE. | Q44092111 | ||
| Tolerability of mycophenolate mofetil in patients with systemic lupus erythematosus. | Q44511575 | ||
| Treatment of lupus psychosis with oral cyclophosphamide followed by azathioprine maintenance: an open-label study | Q44515995 | ||
| P275 | copyright license | Creative Commons Attribution-NonCommercial 3.0 Unported | Q18810331 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 9-20 | |
| P577 | publication date | 2016-01-01 | |
| P1433 | published in | ImmunoTargets and therapy | Q27724782 |
| P1476 | title | Current and emerging treatment options in the management of lupus | |
| P478 | volume | 5 |
| Q50350079 | Curcumin modulation of the activation of PYK2 in peripheral blood mononuclear cells from patients with lupus nephritis |
| Q64263389 | Epoxyeicosatrienoic Acid Analog EET-A Blunts Development of Lupus Nephritis in Mice |
| Q64258702 | Helminth-Based Product and the Microbiome of Mice with Lupus |
| Q92001271 | Mesenchymal Stem Cells Enhance Pulmonary Antimicrobial Immunity and Prevent Following Bacterial Infection |
| Q50102618 | Secular trends in the impact factors of SLE publications over a 45-year period-a systematic review. |
| Q49833678 | Systemic lupus erythematosus and ocular involvement: an overview |
| Q53695276 | Therapeutic plasma exchange for refractory SLE: A comparison of outcomes between different sub-phenotypes. |
| Q50092295 | Unchanging premature mortality trends in systemic lupus erythematosus: a general population-based study (1999-2014). |
Search more.